New research from a team of genome scientists and DNA damage response experts breaks new ground in understanding the function of a protein currently limited in clinical trials for cancer treatments.
In a novel study, researchers from the Icahn School of Medicine at Mount Sinai introduced LoGoFunc, an advanced computational tool that predicts pathogenic gain- and loss-of-function variants across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results